Understanding the new Essilor Stellest spectacle lens


Essilor® Stellest™ lens is one of the newest generation of myopia controlling spectacle lenses, appearing to have efficacy to slow myopia progression in children at least as good as the current 'best' interventions of orthokeratology, dual-focus soft contact lenses and 0.05% atropine.1

Both one-year and two-year randomized control trial data have been published.2,3 In children who wore Stellest lenses for at least 12 hours per day, 7 days per week, their final axial length and myopia was respectively 0.41mm and 0.99D less than children who wore single vision spectacles. The Essilor Stellest lens is designed with Highly Aspherical Lenslet Target ("H.A.L.T.") Technology.

In this article we'll explore the details of this innovative new spectacle lens for myopia control, including research data on its efficacy and visual outcomes. Research on visual functions has also been undertaken indicating that the lens design has minimal impact on distance and near acuity, contrast vision and binocular vision compared to single vision spectacle lens wear.

Stellest lens-revised drawing

The image at left is a schematic to illustrate the Stellest lens. Here are the features.2,4

  • Correction provided by the single vision lens surface
  • Control provided by the H.A.L.T. technology which consists of 11 rings of 1021 contiguous (touching) aspherical lenslets (1.12mm in diameter)
  • Central clear zone of 9mm
  • Within a single ring are lenslets of the same geometry, but lenslets from each ring have different geometries
  • There are spaces between the rings for the single vision distance correction
  • The highly aspherical lenslets create a 'volume of myopic defocus' - read on to learn more.

How does the lens work?

The Essilor® Stellest™ spectacle lens takes the concept of myopic defocus to a new level by introducing the concept of a 'volume of myopic defocus' (VoMD). The concept of relative myopic defocus as a slow-down signal for eye growth is not new, having been demonstrated in animal models as both 'peripheral defocus'5 and 'simultaneous defocus'.6 Whether pictured in your mind as off-axis or on-axis effects, the common theme is creating two contrasting signals: one which falls on the retina to correct ametropia, and one which falls in front of the retina (myopic defocus) to provide the slow-down signal.

We imagine these as focal points, or single planes of focus. Indeed, when we think of an 'add' power in a myopia controlling spectacle or contact lens, this is an accurate way to represent the 'treatment' component of that lens design. By contrast, the VoMD creates a spread of non-focused light rather than the single focus power of an 'add'. This volume is proposed to create a significant slow-down signal for eye growth, based on outcomes of animal models.3

In the image below, the white image shell illustrates this VoMD.

bjophthalmol-2022-August-106-8-1171-F1.large (1)

Figure 1 from Bao et al2 with the following caption: Illustration of the study device providing a volume of myopic defocus (VoMD) (white shell) in front of the retina through 11 concentric rings of contiguous lenslets (A=depth of VoMD and B=distance from the retina). The calculations for the lenslets were based on the modified Atchison eye model using a retinal shape modified to match the peripheral refraction data of Chinese children. Spectacle lenses with highly aspherical lenslets (A=0.7 mm and B=1.2 mm), spectacle lenses with slightly aspherical lenslets (A=0.3 mm and B=1.0 mm) (illustrated and authorised by Dr. Damien Paillé from R&D AMERA, Essilor International).

So what is the 'add' power?

Sorry, you won't get an answer to this one! We're used to thinking about 'add' powers in multifocal soft contact lenses (MFCLs), and of course in spectacle lenses too. The 'add' power in these myopia controlling lenses, though, doesn't work in a traditional sense. The DIMS spectacle lens, with +3.50 Add lenslets, has been shown to not alter accommodation and vergence as we'd expect a traditional add to do in a progressive addition or bifocal spectacle lens.7 Similarly, research in MFCLs has found that different add powers do not differentially influence accommodation in young wearers and instead the design (concentric versus aspheric) has the greater influence.8 Finally, the dual-focus concentric MiSight 1 day contact lens, which has zones of distance correction and a +2.00 Add, has also been shown to not alter binocular vison function.8,9

In the caption for the figure above, you'll see that the VoMD is described in millimetres: the distance that the VoMD is computed to fall in front of the retina,  and the 'spread' of the non-focused light. The differently powered concentric rings have been calculated to follow retinal shape.

The Essilor Stellest lens has been shown to create no change in accommodation lag, accommodation amplitude or near phoria compared to single vision wear in children.10 The VoMD is a new concept, different to an 'add', as the lenslets are not designed to provide a single focal power.

How well does Essilor Stellest lens slow myopia progression?

The two-year clinical study data was published in March 2022. In the study, Chinese children aged 8-13 years with myopia of -0.75D to -4.75D,  astigmatism of no more than 1.50DC and anisometropia of no more than 1.00D were randomized into either single vision (SV), highly aspherical lenslet (HAL) or slightly aspherical lenslet (SAL) spectacle lenses. After two years, 157 children completed the study. Myopia progressed -0.66D/0.34mm in the HAL group, -1.04D/0.51mm in the SAL group and -1.46D/0.69mm in the SV group. This represented around a 50% (0.34mm) axial and 55% (0.80D) refractive efficacy for HAL, and a 26% (0.18mm) axial and 29% (0.41D) refractive efficacy for SAL.3

Daily wearing time was self-reported, with a mean of around 13.5 hours per day, similar across the groups. Compliance improved from 61% wearing their spectacles full-time (at least 12 hours per day, every day) in the first year to 89% in the second year. Full-time wearers showed 0.99D less final myopia and only 0.28mm of total axial growth over two years. This gave a 67% refractive ad 60% axial length control effect compared to single vision lenses.3

The Essilor Stellest lens slowed eye growth to only 0.28mm over two years in children who wore them full-time. Final myopia was reduced by almost 1.00D compared to children wearing single vision.

Recall that 1 diopter less myopia means 40% less potential lifelong risk of myopic maculopathy for a person with myopia.11 This was the mean achievement over only two years of full-time wear!

Vision and visual function outcomes

Here are the main findings from the studies which have been undertaken, comparing Essilor Stellest lenses to single vision and other myopia controlling spectacle lenses.

  • Essilor Stellest spectacle lenses have shown no visual acuity difference compared to single vision spectacles at distance or near2
  • When viewing through the lenslet zone, distance acuity is reduced by 0.07 logMAR units, which is 3.5 letters. A direct comparison to the DIMS honeycomb lenslet configuration spectacle found it also reduced acuity, by 0.09 logMAR or 4.5 letters. This difference was statistically significant, but practically is only 1 letter different.4
  • Accommodation lag, accommodation amplitude and near phoria were unaffected by the lenslets11
  • Glare has minimal impact on vision through the lenslet zone. Acuity in lower illumination settings and with low contrast text is slightly impacted.4

The bottom line: wearing time matters

Let me say it again: full-time wear is of utmost importance if we are going to maximize treatment outcomes with the Essilor Stellest lens. This is also true of other myopia control treatments. In the dual-focus MiSight 1 day contact lens clinical trial, the strong results were achieved with a mean wearing time of around 13.5 hours per day, 6.5 days per week.12 The DIMS spectacle lens clinical trial did not measure an effect of wearing time, but compliance was strong, reported as more than 15 hours per day.7

If we want to achieve the strongest myopia control results for our patients, we need to encourage and reinforce the importance of full-time wear: at least 12 hours per day, every day.

Which myopia treatment should you prescribe?

How does the Essilor Stellest lens compare to other myopia control treatments? Very favourably! We do need to apply caution in direct comparison between studies, as differences in study duration and control group characteristics influence the outcomes, especially the reported percentages. Comparing the absolute control effects between studies is possible, though, with a focus on reduction in axial length growth rate, as this is the more accurate measure and the main goal for myopia control.1

The Essilor Stellest lens reduced axial growth by 0.35mm on average across the study participants, with 0.41mm reduction in children who wore them full-time.2 Compared to other myopia controlling spectacle interventions, axial length over two years was slowed 0.34mm in the DIMS spectacle lens, 0.21mm in bifocal and prismatic bifocal and only 0.10mm in progressive addition spectacles.13 Direct statistical comparisons of these figures have not been undertaken to point out which are significantly different (or which may be similar), but we can consider these strong results to be at least as good as what has been reported in ortho-k, dual-focus MiSight and 0.05% atropine studies.1

The simple message is to prescribe anything other than single vision, which suits the child and fits your scope of practice. Arguably, all myopic children need spectacles - even if they're a full-time contact lens wearer - so it's fantastic to have spectacle treatment options like the Essilor Stellest lens, which can at least match the efficacy results of our leading treatments to date.

Further reading

Kate profile thumbnail

About Kate

Dr Kate Gifford is a clinical optometrist, researcher, peer educator and professional leader from Brisbane, Australia, and a co-founder of Myopia Profile.

This educational content is brought to you thanks to unrestricted educational grant from


  1. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2020 Nov 27:100923. (link) [Link to Myopia Profile paper review]
  2. Bao J, Yang A, Huang Y, Li X, Pan Y, Ding C, Lim EW, Zheng J, Spiegel DP, Drobe B, Lu F, Chen H. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-1176. (link) [Link to Myopia Profile Science Summary]
  3. Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen H. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 2022 May 1;140(5):472-478. (link) [Link to Myopia Profile Science Summary]
  4. Li X, Ding C, Li Y, Lim EW, Gao Y, Fermigier B, Yang A, Chen H, Bao J. Influence of Lenslet Configuration on Short-Term Visual Performance in Myopia Control Spectacle Lenses. Front Neurosci. 2021 May 25;15:667329. (link) [Link to Myopia Profile Science Review]
  5. Smith EL 3rd. Prentice Award Lecture 2010: A case for peripheral optical treatment strategies for myopia. Optom Vis Sci. 2011 Sep;88(9):1029-44. (link)
  6. Smith Iii EL, Arumugam B, Hung LF, She Z, Beach K, Sankaridurg P. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res. 2020 Dec;177:32-40. (link)
  7. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020 Mar;104(3):363-368. (link)  [Link to Myopia Profile Science Review]
  8. Gifford KL, Schmid KL, Collins JM, Maher CB, Makan R, Nguyen E, Parmenter GB, Rolls BM, Zhang XS, Atchison DA. Multifocal contact lens design, not addition power, affects accommodation responses in young adult myopes. Ophthalmic Physiol Opt. 2021 Nov;41(6):1346-1354. (link)
  9. Ruiz-Pomeda A, Pérez-Sánchez B, Cañadas P, Prieto-Garrido FL, Gutiérrez-Ortega R, Villa-Collar C. Binocular and accommodative function in the controlled randomized clinical trial MiSight® Assessment Study Spain (MASS). Graefes Arch Clin Exp Ophthalmol. 2019 Jan;257(1):207-215. (link) [Link to Myopia Profile Science Review]
  10. Huang Y, Li X, Wang C, Zhou F, Yang A, Chen H, Bao J. Visual acuity, near phoria and accommodation in myopic children using spectacle lenses with aspherical lenslets: results from a randomized clinical trial. Eye Vis (Lond). 2022 Sep 1;9(1):33. (link)
  11. Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci. 2019;96(6):463-5. (link)  [Link to Myopia Profile Article]
  12. Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567. (link)  [Link to Myopia Profile Science Review]
  13. Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500. (link)